Pfizer (PFE) Non-Current Debt (2009 - 2026)

Pfizer has disclosed Non-Current Debt across 18 years of filings, most recently posting $60.6 billion for Q1 2026.

• In Q1 2026, Non-Current Debt rose 5.08% year-over-year to $60.6 billion; the TTM figure through Mar 2026 stood at $60.6 billion (up 5.08% YoY), while the FY2025 annual figure was $61.6 billion, up 8.14% from the prior year.
• Non-Current Debt retreated to $60.6 billion in Q1 2026, from $61.6 billion in the prior quarter.
• Over the last five years, Non-Current Debt for PFE reached as high as $61.6 billion in Q4 2025 and fell as low as $31.7 billion in Q2 2023.
• The 5-year median for Non-Current Debt is $57.5 billion (2024), against an average of $51.7 billion.
• Annual changes were most pronounced in 2023 — Non-Current Debt dropped 11.08% — and 2024, when it soared 93.37%.
• A 5-year view of Non-Current Debt shows it stood at $32.9 billion in 2022, then soared by 87.14% to $61.5 billion in 2023, then dropped by 7.37% to $57.0 billion in 2024, then increased by 8.14% to $61.6 billion in 2025, then fell by 1.75% to $60.6 billion in 2026.
• According to Business Quant data, Non-Current Debt over the past three periods registered $60.6 billion, $61.6 billion, and $57.4 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.